Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1CNS 1

Conditions

Carcinoma, Renal Cell 29Carcinoma, Hepatocellular 16Prostatic Neoplasms 12Neoplasm Metastasis 11Carcinoma, Non-Small-Cell Lung 9Neoplasms 8Sarcoma 7Osteosarcoma 6Neuroendocrine Tumors 6Brain Neoplasms 6Urinary Bladder Neoplasms 5Kidney Neoplasms 5Carcinoma, Transitional Cell 5Breast Neoplasms 5Sarcoma, Ewing 4Melanoma 4Lung Neoplasms 4Recurrence 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Clear-cell metastatic renal cell carcinoma 3Carcinoid Tumor 3Adrenocortical Carcinoma 3Adenocarcinoma 3Wilms Tumor 2Uterine Cervical Neoplasms 2Urethral Neoplasms 2Thyroid Neoplasms 2Thyroid Diseases 2Thyroid Cancer, Papillary 2

Interventions

Cyclophosphamide 34Etoposide 25Doxorubicin 20Carboplatin 20Vincristine 19Isotretinoin 19Topotecan 17Temozolomide 17Irinotecan 16Filgrastim 16Melphalan 15Cisplatin 15sargramostim 14Radiotherapy 14Granulocyte-Macrophage Colony-Stimulating Factor 133-Iodobenzylguanidine 12dinutuximab 11Peripheral Blood Stem Cell Transplantation 11naxitamab 9Thiotepa 9Magnetic Resonance Spectroscopy 9humanized 3F8 anti-GD2 monoclonal antibody 7Granulocyte Colony-Stimulating Factor 7Busulfan 7X-Rays 6Specimen Handling 6Phantoms, Imaging 6Ifosfamide 6Antilymphocyte Serum 6fludarabine phosphate 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neuroblastoma × cabozantinib × Clear all
NCT05135975 2025-08-12

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

Nationwide Children's Hospital

Phase 2 Recruiting
86 enrolled
CNSGenitourinarySarcoma

Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡